Stay updated on Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial page.

Latest updates to the Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page's revision note updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check18 days agoChange DetectedThe notice about government funding and operating status has been removed from the page. This information is administrative and does not affect the study details, eligibility criteria, or contact information.SummaryDifference0.4%

- Check33 days agoChange DetectedNote added to Study Record Dates showing the last known status as reported by National Cancer Centre, Singapore on 2023-10 and marked as Verified Unknown status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check40 days agoChange DetectedThe new screenshot shows minor UI refinements such as spacing, typography, and small layout adjustments across sections; there are no changes to core study details like eligibility criteria, endpoints, enrollment, or location. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check62 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference3%

- Check69 days agoChange DetectedUpdated page version to v3.1.0 and added a new contact phone number; removed the previous version tag v3.0.2.SummaryDifference0.1%

Stay in the know with updates to Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial page.